retatrutide phase 2 trial obesity type 2 diabetes is investigational and is not FDA approved. In TRANSCEND retatrutide phase 2 trial type

However, its important to note: Weight management can be a valuable secondary outcome for people with T2DM, as it often improves insulin sensitivity, lowers cardiovascular risk, and enhances overall metabolic health 4 , 10

Check, check, check

BENEFITS: Regulates mitochondrial function

By week 4 on doses of 4mg and above, participants showed 14.0 to 19.5 point reductions in sweet food desire compared to placebo

doi: 10.1172/JCI146353 Summary Keywords GIP, GLP-1, tirzepatide, basal insulin, type 2 diabetes, obesity, body weight, hypoglycemia Citation Lisco G, De Tullio A, Disoteo O, De Geronimo V, Piazzolla G, De Pergola G, Giagulli VA, Jirillo E, Guastamacchia E, Sabb C and Triggiani V (2022) Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis

3.1 Liu lng ph hp lm quen Vi ngi mi, nng t 100mg mi ngy dng ngm di li l c th bt u qu trnh thi c v h tr chuyn i sc t da